Cytokinetics (NASDAQ:CYTK) Posts Earnings Results, Beats Expectations By $0.06 EPS

Cytokinetics (NASDAQ:CYTK) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.06, Zacks reports. The company had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. During the same quarter last year, the firm posted ($2.55) earnings per share. The firm’s revenue was up 2356.5% on a year-over-year basis.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO generated $44.5 million in Q3 net product revenue, up 76% sequentially. Prescribers and dispensed patients grew, while new-to-brand share approached 45%; the company is targeting more than 50% by year-end.
• Cytokinetics plans to submit an aficamten supplemental NDA for symptomatic non-obstructive HCM this quarter, following positive Phase 3 ACACIA-HCM results. The company is also preparing for a potential 2027 launch, though approval and the eventual label remain uncertain.
• MYQORZO’s international rollout is progressing, with Germany showing early traction and a U.K. launch expected this quarter. The company expects launches in additional countries in 2027, while noting broader European revenue may take until 2028–2029 to build meaningfully.
• The company ended Q3 with approximately $1.6 billion in cash and investments and reaffirmed 2026 combined R&D and SG&A expense guidance of $860 million–$890 million. Quarterly SG&A increased to $113.1 million as commercial launch costs rose, while the company reported a $190.1 million net loss.

Cytokinetics Stock Down 13.4%

CYTK stock traded down $8.54 during trading on Thursday, hitting $55.06. 2,225,681 shares of the company’s stock traded hands, compared to its average volume of 2,091,361. The firm has a market capitalization of $6.85 billion, a P/E ratio of -7.57 and a beta of 0.45. Cytokinetics has a 1 year low of $54.92 and a 1 year high of $88.31. The business has a fifty day simple moving average of $66.63 and a two-hundred day simple moving average of $70.05.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CYTK shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research note on Friday, September 11th. Citizens Jmp upped their price target on Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research note on Friday, August 7th. Needham & Company LLC raised their price objective on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Royal Bank Of Canada lifted their price objective on Cytokinetics from $112.00 to $113.00 and gave the company an “outperform” rating in a research note on Thursday, October 8th. Finally, Wall Street Zen downgraded Cytokinetics from a “hold” rating to a “sell” rating in a report on Tuesday, October 20th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $105.44.

Insiders Place Their Bets

In other news, Director B. Parshall sold 5,000 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total transaction of $357,400.00. Following the sale, the director directly owned 10,784 shares of the company’s stock, valued at $770,840.32. This represents a 31.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of Cytokinetics stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $68.29, for a total transaction of $239,015.00. Following the completion of the sale, the executive vice president directly owned 153,902 shares in the company, valued at $10,509,967.58. This represents a 2.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 180,926 shares of company stock valued at $12,510,340. Company insiders own 2.60% of the company’s stock.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Q3 results topped expectations. Cytokinetics reported a loss of $1.37 per share, narrower than the $1.43 analyst estimate and $2.55 loss a year earlier. Revenue of $47.56 million beat the $41.88 million consensus and rose sharply year over year, supporting the view that the business is progressing. Cytokinetics Q3 Loss Narrows, Revenue Rises
• Positive Sentiment: Aficamten and MYQORZO could provide further growth drivers. Recent coverage highlights aficamten data and the potential effect of MYQORZO adoption, which investors may view as important to the company’s commercial outlook. A separate valuation article argues CYTK could be 41% undervalued, though that is an estimate rather than a guaranteed return. Valuation and aficamten article MYQORZO adoption article
• Negative Sentiment: Losses continue. Despite the year-over-year improvement and earnings beat, Cytokinetics still reported a quarterly net loss, so investors will look for sustained revenue growth and progress toward profitability. Q3 loss and revenue estimates
• Neutral Sentiment: Insider sale was under a pre-arranged plan. EVP Fady Malik sold 3,500 shares, about 2.22% of his holdings, but the transaction was conducted under a Rule 10b5-1 plan, which makes it a less direct signal about near-term business prospects. Insider sale report

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.